Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma:Based on muti-omics analysis and vitro assay

Advanced LUAD shows limited response to treatment including immune therapy.With the development of sequencing omics,it is urgent to combine high-throughput multi-omics data to identify new immune checkpoint therapeutic response markers.Using GSE72094(n=386)and GSE31210(n=226)gene expression profile data in the GEO database,we identified genes associated with lung adenocarcinoma(LUAD)death using tools such as“edgeR”and“maftools”and visualized the characteristics of these genes using the“circlize”R package.We constructed a prognostic model based on death-related genes and optimized the model using LASSO-Cox regression methods.By calculating the cell death index(CDI)of each individual,we divided LUAD patients into high and low CDI groups and examined the relationship between CDI and overall survival time by principal component analysis(PCA)and Kaplan-Meier analysis.We also used the“ConsensusClusterPlus”tool for unsupervised clustering of LUAD subtypes based on model genes.In addition,we collected data on the expression of immunomodulatory genes and model genes for each cohort and performed tumor microenvironment analyses.We also used the TIDE algorithm to predict immunotherapy responses in the CDI cohort.Finally,we studied the effect of PRKCD on the proliferation and migration of LUAD cells through cell culture experiments.The study utilized the TCGA-LUAD cohort(n=493)and identified 2,901 genes that are differentially expressed in patients with LUAD.Through KEGG and GO enrichment analysis,these genes were found to be involved in a wide range of biological pathways.The study also used univariate Cox regression models and LASSO regression analyses to identify 17 candidate genes that were best associated with mortality prognostic risk scores.By comparing the overall survival(OS)outcomes of patients with different CDI values,it was found that increased CDI levels were significantly associated with lower OS rates.In addition,the study used unsupervised cluster analysis to divide 115 LUAD patients into two distinct clusters with significant differences in OS timing.Finally,a prognostic indicator called CDI was established and its feasibility as an independent prognostic indicator was evaluated by Cox proportional risk regression analysis.The immunotherapy efficacy was more sensitive in the group with high expression of programmed cell death models.Relationship between programmed cell death(PCD)signature models and drug reactivity.After evaluating the median inhibitory concentration(IC50)of various drugs in LUAD samples,statistically significant differences in IC50 values were found in cohorts with high and low CDI status.Specifically,Gefitinib and Lapatinib had higher IC50 values in the high-CDI cohort,while Olaparib,Oxaliplatin,SB216763,and Axitinib had lower values.These results suggest that individuals with high CDI levels are sensitive to tyrosine kinase inhibitors and may be resistant to conventional chemotherapy.Therefore,this study constructed a gene model that can evaluate patient immunotherapy by using programmed cell death-related genes based on muti-omics.The CDI index composed of these programmed cell death-related genes reveals the heterogeneity of lung adenocarcinoma tumors and serves as a prognostic indicator for patients.

Analysis of the Efficacy,Progression-Free Survival,and Safety of Anlotinib in Advanced Lung Cancer Treatment

Objective:To analyze the clinical efficacy,progression-free survival,and safety of anlotinib in the treatment of advanced lung cancer.Methods:A retrospective analysis was conducted using data from 60 patients with advanced lung cancer treated with anlotinib from May 2019 to May 2021.This analysis aimed to comprehensively evaluate the clinical efficacy,progression-free survival,and adverse reactions of anlotinib.Results:The median progression-free survival(PFS)for the 60 patients was 5.79 months,with an overall response rate(ORR)of 21%and a disease control rate(DCR)of 90%.In the first-line group,the median PFS was 6.20 months,ORR was 76.92%,and DCR was 84.61%.The second-line group showed a median PFS of 6.30 months,ORR of 28.57%,and DCR of 90.48%.In the third-line group,the median PFS was 5.34 months,ORR was 19.23%,and DCR was 92.30%.The single-agent group exhibited a median PFS of 5.09 months,ORR of 23.33%,and DCR of 76.67%.In the combination group,the median PFS was 6.53 months,ORR was 46.67%,and DCR was 100%.The combination group demonstrated a significantly higher medication effect than the single-drug group,and adverse drug reactions were mostly grade 1-2.Conclusion:Anlotinib exhibits a better disease control rate and survival benefit in the treatment of advanced lung cancer.The combination effect is superior to monotherapy,with relatively controllable adverse effects.

Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer

The phamacogenetics is being used to predict whether the selected chemotherapy will be really effective and tolerable to the patient. Irinotecan,oxidized by CYP3A4 to produce inactive compounds,is used for treatment of various cancers including advanced non small cell lung cancer (NSCLC) patients. CYP3A4*16B polymorphism was associated with decreased metabolism of irrinotecan. Irinotecan is also metabolized by carboxylesterase to its principal active metabolite,SN-38,which is subsequently glucuronidated by UGT1As to form the inactive compound SN-38G. UGT1A1*28 and UGT1A1*6 polymorphisms were useful for predicting severe toxicity with NSCLC patients treated with irinotecan-based chemotherapy. Platinum-based compounds (cisplatin,carboplatin) are being used in combination with new cytotoxic drugs such as gemcitabine,paclitaxel,docetaxel,or vinorelbine in the treatment of advanced NSCLC. Cisplatin activity is mediated through the formation of cisplatin-DNA adducts. Gene polymorphisms of DNA repair factors are therefore obvious candidates for determinants of repair capacity and chemotherapy efficacy. ERCC1,XRCC1 and XRCC3 gene polymorphisms were a useful marker for predicting better survival in advanced NSCLC patients treated with platinum-based chemotherapy. XPA and XPD polymorphisms significantly increased response to platinum-based chemotherapy. These DNA repair gene polymorphisms were useful as a predictor of clinical outcome to the platinum-based chemotherapy. EGFR kinase inhibitors induce dramatic clinical responses in NSCLC patients with advanced disease. EGFR gene polymorphism in intron 1 contains a polymorphic single sequence dinucleotide repeat (CA-SSR) showed a statistically significant correlation with the gefitinib response and was appeared to be a useful predictive marker of the development of clinical outcome containing skin rashes with gefitinib treatment. The other polymorphisms of EGFR were also associated with increased EGFR promoter activity. EGFR gene mutations and polymorphisms were also associated with EGFR kinase inhibitors response and toxicity.

The Therapeutic Effects of the Radiotherapy Plus TCM Treatment Observed in Senile Non-Parvicellular Lung Cancer Patients at the Late Stage

47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases) treated only by radiotherapy for observation of the therapeutic effects.The patients in the treatment group orally took Chinese medicine during and after the radiotherapy.There was no obvious difference in short-term therapeutic effects between the two groups,but the long-term curative effects in the treatment group was obviously superior to that in the control group (P<0.05 or P<0.01).Conclusion:radiotherapy plus TCM can prolong the survival period for senile non-parvicellular lung cancer patients.

Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer(2022 edition)

Lung cancer is the leading cause of cancer-related deaths worldwide.Bone is a common metastatic site of lung cancer,about 50%of bone metastatic patients will experience skeletal related events(SREs).SREs not only seriously impact the quality of life of patients,but also shorten their survival time.The treatment of bone metastasis requires multi-disciplinary therapy(MDT)and development of individualized treatment plan.In order to standardize the diagnosis and treatment of bone metastasis in lung cancer,the expert group of the MDT Committee of the Chinese Medical Doctor Association has developed the expert consensus on the diagnosis and treatment of lung cancer bone metastasis.

免疫细胞及炎症因子对晚期肺癌一线化疗效果的预测价值

【目的】探讨T淋巴细胞亚群、肿瘤浸润T淋巴细胞(Tils)及炎症因子对晚期肺癌一线化疗效果的预测价值。【方法】检测98例首诊TNM分期为Ⅲ/Ⅳ期的非小细胞肺腺癌患者的血清白细胞介素1α(IL-1α)、IL-6、IL-17、γ-干扰素(INF-γ)水平及T淋巴细胞亚群CD4^(+)T、CD8^(+)T、调节性T细胞、CD57^(+)细胞、Granzyme B^(+)细胞、CD45RO^(+)细胞比例;所有患者均接受紫杉醇注射液+顺铂化疗,治疗4个周期后评定疗效,并据此分为有效组和无效组,分析化疗无效的影响因素及预测疗效的有效标志物。【结果】化疗后,98例患者中69例化疗有效,29例无效。无效组患者淋巴结转移占比及调节性T细胞、IL-1α表达水平均高于有效组(P<0.05),CD57^(+)细胞、CD45RO^(+)细胞比例均低于有效组(P<0.05)。多因素逐步Logistic回归分析结果显示,调节性T细胞、IL-1α水平高是肺癌患者化疗无效的危险因素(P<0.05),CD57^(+)细胞、CD45RO^(+)细胞比例高是保护因素(P<0.05)。受试者工作特征(ROC)曲线分析显示,调节性T细胞、CD57^(+)细胞、CD45RO^(+)细胞、IL-1α水平预测化疗效果的灵敏度分别为82.76%、86.21%、89.66%、93.10%,四者联合的灵敏度、特异度和曲线下面积(AUC)分别为82.76%、97.10%、0.957。【结论】T淋巴细胞亚群、Tils及炎症因子水平与晚期肺癌治疗效果密切相关,其可作为预测疗效的敏感指标。

奥希替尼在老年非小细胞肺癌患者靶向治疗中的应用效果及对T细胞水平的影响

目的 探讨奥西替尼在老年非小细胞肺癌患者靶向治疗中的效果及对免疫水平的影响。方法 回顾性选择2018年1月至2020年12月老年非小细胞肺癌患者116例研究,根据治疗方法不同分为2组,各58例。对照组采用常规放化疗治疗,观察组在对照组基础上联合奥西替尼治疗,3个月治疗后评估患者效果,比较2组总有效率、T细胞水平(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、肿瘤标志物水平、不良反应发生率。结果 观察组治疗3个月总有效率为44.8%高于对照组25.9%(P<0.05);2组治疗后3个月CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均低于治疗前(P<0.05);CD8^(+)水平高于治疗前(P<0.05);观察组治疗后3个月CD3^(+)(58.95±4.21)%、CD4^(+)(32.59±3.11)%、CD4^(+)/CD8^(+)(1.21±0.22)高于对照组(P<0.05);CD8^(+)(26.81±3.32)%低于对照组(P<0.05);观察组干预3个月后CA125(91±8)U/ml、CYFRA21-1(1.26±0.24)μg/L及癌胚抗原(CEA)水平(34±5)μg/L均低于对照组(P<0.05);2组不良反应发生率差异无统计学意义(P>0.05)。结论 奥西替尼用于老年非小细胞肺癌患者靶向治疗中,能获得较好的总有效率,对患者T细胞水平影响较小,可降低肿瘤标志物水平,未增加不良反应发生率,值得临床推广应用。

互联网+多元联动延续性护理模式在肺癌靶向药物治疗病人中的应用效果

目的:研究互联网+多元联动延续性护理模式在肺癌靶向药物治疗病人中的应用效果。方法:选取2022年1月-12月接诊的160例肺癌靶向药物治疗病人作为研究对象。按随机数字表法随机分为研究组与对照组各80例,对照组给予常规护理,研究组给予互联网+多元联动延续性护理模式护理。在护理前及护理3个月后分别记录并比较两组病人的用药依从性评分、自我护理能力评分、生活质量(角色功能、社会功能、认知功能、躯体功能、心理功能)评分;在护理3个月后记录并比较两组病人的不良反应发生率和护理满意度。结果:护理后,两组病人的用药依从性评分、自我护理能力评分、生活质量评分均明显升高,且研究组明显高于对照组,差异有统计学意义(P<0.05);研究组病人不良反应总发生率为12.50%,明显低于对照组的27.50%,差异有统计学意义(P<0.05);研究组病人护理总满意度为92.50%,明显高于对照组病人的80.00%,差异有统计学意义(P<0.05)。结论:互联网+多元联动延续性护理模式在肺癌靶向药物治疗病人中的应用效果显著,可有效提高病人的用药依从性、自我护理能力和护理满意度,有利于改善病人的生活质量,降低不良反应发生率。

中药联合抗肿瘤血管生成药物治疗非小细胞肺癌的研究进展

非小细胞肺癌(NSCLC)是肺癌最为常见的一种病理类型,一半以上的患者确诊时即为进展期肺癌,患者生存期较短。抗肿瘤血管生成药物是目前治疗非小细胞肺癌的重要靶向药物,其临床疗效已获得临床认可,但仍存在耐药性及毒副作用不可耐受的局限性,而中药辨证论治及减毒增效的优点,可减轻药物的不良反应,并提高临床疗效,已成为中西医结合治疗非小细胞肺癌的重要方向。本文主要通过检索2010年1月—2023年6月中国知网、万方、维普及PubMed等数据库中的相关文献,总结近年来不同中药联合各类抗肿瘤血管生成药物治疗NSCLC的相关研究,试从不同角度探讨治疗NSCLC的新思路。

SENP1在肺癌病理生物学中的作用

SENP1是一种参与去SUMO化的蛋白质,是肿瘤发生和复发、转移的一个危险因素,与多种肿瘤的发生、侵袭、转移及耐药相关,其在肿瘤组织中的表达具有十分重要的意义。SENP1通过与多种分子、靶蛋白相互作用调控细胞周期、促进肿瘤血管生成、参与细胞铁死亡等,导致肺癌的复发和转移,是肺癌患者预后不良的影响因素。本文对SENP1及其靶蛋白在肿瘤发生发展中的作用机制、对肺癌耐药和预后的影响进行总结。

气管镜下介入联合药物注射治疗中央型非小细胞肺癌疗效与安全性研究

目的:评价气管镜下介入联合瘤体药物注射方法对于中央型非小细胞肺癌(non-small cell lung cancer,NSCLC)的有效性和安全性。方法:符合试验入排标准的64名患者,对纳入试验的患者按照1∶1的比例随机分配试验组和对照组,分别给予支气管镜下介入及局部注射顺铂、重组人血管内皮抑素联合含铂双药化疗与单纯含铂双药化疗,比较两组的疗效以及安全性。结果:与对照组相比,试验组患者Karnofsky功能状态(karnofsky performance status,KPS)评分、气促分级均得到明显改善(P<0.05)。试验组的治疗总有效率为78.12%,对照组的总有效率为37.5%,两组间比较差异具有统计学意义(P<0.05),两组生存情况比较差异有统计学意义(P<0.05)。结论:经支气管镜介入联合药物注射治疗中央型NSCLC临床疗效显著,能有效改善临床症状,提高患者生存质量。两组患者不良反应比较,无显著差异,值得推广应用。

肺癌骨转移治疗中纳米材料应用的研究进展

根据世界卫生组织国际癌症研究机构(IARC)发布的“2020年全球新发癌症病例”报道,全球肺癌新发病例约220万例,死亡约180万例,肺癌是癌症死亡的主要原因。肺癌骨转移发生率为30%~40%,46%的肺癌骨转移患者并发疼痛、高钙血症、病理性骨折等骨相关事件(SRE)^([1,2])。

滋肾润肺方辅助化疗治疗中晚期肺癌气阴两虚证患者的临床疗效

【目的】探讨滋肾润肺方联合化疗治疗中晚期肺癌气阴两虚证患者的疗效。【方法】两院收治的80例中晚期肺癌气阴两虚证患者,随机分为化疗组与联合组,每组40例。化疗组采用常规肺癌化疗方案,联合组在此基础上同时给予滋肾润肺方口服。比较两组患者的疗效、疾病进展时间(TTP)、1年存活率、1年无进展生存(PFS)率,治疗前后中医症状积分、卡氏评分(KPS)改善情况,骨髓抑制发生情况。【结果】联合组治疗总有效率(RR)为37.5%(15/40)、疾病控制率(DCR)为82.5%(33/40),化疗组RR为27.5%(11/40)、DCR为70.0%(28/40),两组比较差异均无统计学意义(P>0.05)。化疗组TTP为6.5(4.2~8.4)个月,1年存活率为30.0%(12/40),1年PFS率为85.0%(34/40);联合组TTP为7.2(5.5~9.3)个月,1年存活率35.0%(14/40),1年PFS率为87.5%(35/40),两组比较差异均无统计学意义(P>0.05)。与治疗前比较,两组治疗后中医症状积分均明显降低,且观察组各项指标下降更显著(P<0.05)。治疗后,联合组KPS评分稳定率为90.00%(36/40),明显高于化疗组的70.00%(28/40)(P<0.05)。联合组骨髓抑制的总发生率为17.5%(7/40),低于化疗组的42.5%(17/40)(P<0.05)。【结论】滋肾润肺方联合化疗可有效改善患者的生活质量,且能降低骨髓抑制的发生率。

非小细胞肺癌获得性耐药和表皮生长因子受体靶向治疗耐受机制研究进展

目的探讨靶向表皮生长因子受体(EGFR)的特异性酪氨酸激酶抑制剂(EGFR-TKIs)在治疗该靶点突变的非小细胞肺癌(NSCLC)中的研究进展。方法重点讨论EGFR的靶向治疗方案,并详细阐述EGFR-TKIs的耐药机制,以及耐药持久性(DTP)细胞的特征和EGFR突变导致NSCLC耐药的机制基础。结果EGFR靶向治疗疗效显著,但会引起药物耐受或耐药细胞的出现,最终导致肿瘤复发。结论深入研究药物耐受性和获得性耐药的根本原因,有助于提高癌症治疗的效果。

药物罐疗法在气阴两虚型肺癌患者中的应用效果

目的探讨药物罐疗法在气阴两虚型肺癌患者中的应用效果。方法选取2022年10月—2023年6月江苏省中医院收治的80例气阴两虚型肺癌患者作为研究对象,应用随机数表法将其分为观察组与对照组,每组40例。对照组采取常规干预,观察组在对照组基础上增加药物罐疗法。对比两组中医证候积分,疼痛数字评分法(NRS)评分,血液流变学,以及癌因性疲乏程度与生存质量。结果干预前两组患者主症、次症相关中医证候积分对比,差异无统计学意义(P>0.05),干预后两组患者主症、次症相关中医证候积分均降低,且观察组低于对照组(P<0.05);干预前两组患者NRS评分对比,差异无统计学意义(P>0.05),干预后两组患者评分均降低,且观察组低于对照组(P<0.05);干预前两组血液流变学指标对比,差异无统计学意义(P>0.05),干预后两组血浆比粘度、高切全血比粘度、低切全血比粘度均降低,且观察组低于对照组(P<0.05);干预前两组患者PFS-R、WHOQOL-BREF评分对比,差异无统计学意义(P>0.05),干预后两组患者PFS-R评分均降低,且观察组低于对照组,WHOQOL-BREF评分升高,且观察组高于对照组(P<0.05)。结论药物罐疗法可改善气阴两虚型肺癌患者中医症状,减轻癌因性疼痛程度,改善血液流变学水平,减轻癌因性疲乏程度,提升患者生存质量。

非小细胞肺癌第三代ALK抑制剂洛拉替尼的耐药机制及其相关研究进展

间变淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因是非小细胞肺癌(non-small cell lung cancer,NSCLC)患者除表皮生长因子受体(epidermal growth factor receptor,EGFR)基因之外最常见的驱动基因。ALK融合基因阳性的NSCLC患者能从ALK酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)靶向治疗中明显获益,但是患者最终会发生TKI耐药。探索ALK靶向治疗的耐药机制一直是研究重点。关于第一代和第二代ALK TKIs的耐药机制已有较多报道,第三代ALK TKI洛拉替尼的耐药机制亟待阐述。本文将主要从依赖ALK基因(即on-target resistance)和非依赖ALK基因(即off-target resistance)两方面阐述第三代ALK TKI洛拉替尼的耐药机制,重点总结了经序贯洛拉替尼治疗发生复合突变后对其他TKIs的敏感性以及旁路活化途径,一线洛拉替尼治疗潜在的耐药机制以及第四代ALK TKIs的研究进展,洛拉替尼治疗中液体活检动态监测的意义。

针刺联合药罐疗法治疗慢性阻塞性肺疾病急性加重期临床研究

目的:观察针刺联合药罐疗法治疗慢性阻塞性肺疾病急性加重期疗效。方法:选取86例慢性阻塞性肺疾病急性加重期患者,按随机数字表法分为对照组、研究组各43例,对照组给予常规现代医学治疗,研究组在对照组基础上给予针刺联合药罐疗法治疗。比较2组临床疗效,比较2组治疗前后中医证候评分、肺功能指标值[用力肺活量(FVC)、第1秒用力呼气量(FEV_(1))、第1秒用力呼气量/用力肺活量(FEV_(1)/FVC)]、血气参数[动脉血氧分压(PaO_(2))、二氧化碳分压(PaCO_(2))、酸碱度(pH)、血氧饱和度(SaO_(2))]、炎症因子[C-反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)]水平的变化。结果:研究组临床疗效总有效率为97.67%,对照组为83.72%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组咳嗽喘息、咳痰、发热口干、心悸、大便干结中医证候积分均较治疗前下降(P<0.05),研究组上述5项中医证候积分均低于对照组(P<0.05)。治疗后,2组FVC、FEV_(1)、FEV_(1)/FVC水平均较治疗前上升(P<0.05),研究组上述3项水平均高于对照组(P<0.05)。治疗后,2组PaO_(2)、pH、SaO_(2)参数值均较治疗前上升(P<0.05),PaCO_(2)参数均较治疗前下降(P<0.05);研究组PaO_(2)、pH、SaO_(2)参数值均高于对照组(P<0.05),PaCO_(2)参数低于对照组(P<0.05)。治疗后,2组CRP、IL-6、IL-1β水平均较治疗前下降(P<0.05),研究组上述3项炎症因子水平均低于对照组(P<0.05)。结论:针刺联合药罐疗法治疗慢性阻塞性肺疾病急性加重期临床效果较好,能有效缓解临床症状,降低炎症因子水平,提高肺功能,改善血气指标。

THE CLINICAL COURSE AND TREATMENT RESULTS OF LUNG METASTASES FROM BREAST CANCER

Objective: To analyze the clinical course and treatment result of lung metastases from breast cancer Method: 122 cases with lung metastases from breast cancer were treated with chemotherapy or chemotherapy plus endocrine therapy, response was assessed according to WHO criteria and survival rate estimated using the life Table Results: The median time from initial treatment of primary tumor to lung metastases was 22 months Sites of common consecutive metastases were lung, liver and bone The overall response rate was 48% with a CR rate of 15% Compared to non DDP encompassing regimen, the CR rate was higher in DDP based chemotherapy (7% versus 21%, P <0 05) with a longer median survival time (MST) The PR rate was higher in regimens containing anthracycline (48%) than in those without anthracycline (20%, P <0 01) The response rate was similar between chemotherapy and chemotherapy plus endocrine therapy ( P >0 05) No difference in MST was observed between patients receiving anthracycline and non anthracycline encompassing regimens The 1 , 3 , 5 , and 10 year survival rate was 77%, 22%, 11%, and 10%, respectively Conclusion: Size of primary tumor, the length of disease free interval, the number of lung metastases may provide additional information for predicting patients survival after treatment of lung metastases Combination chemotherapy, especially DDP based chemotherapy may prolong survival time of patients with lung metastases from breast cancer

Analyze the rules of Chinese herbal of Professor Xiong Lu in treating metaphase and advanced lung cancer by data mining

Objective： To analyze the experience of chief physician Xiong Lu in treating metaphase and advanced lung cancer through using TCM inheritance support system （V2.5）. Methods： Collecting the prescriptions used for metaphase and advanced lung cancer from November 1, 2014 to February 1, 2015, then the data were entered into the TCM inheritance support system. Based on principle analysis, revised mutual information, complex system entropy cluster and unsupervised hierarchical clustering composing principles were analyzed. Results： Based on the analysis of 228 cases of prescriptions, the frequency of each Chinese medicinal herb and association rules among herbs included in the database were computed. 15 core combinations and 2 new prescriptions were explored from the database. Conclusion： In treating metaphase and advanced lung cancer, chief physician Xiong Lu pay attention to Fuzheng Peiben （Therapy for support Zheng-qi to propup root）, according to the different situation cooperate with Tong Luo （dredging collaterals）, San Jie （Dissipating a mass）, Huo Xue （Activating blood）, Gong Du （Counteracting toxic substance） and so on. Xiong Lu is also good at using toxic drugs and incompatible medicaments.